key: cord-0780517-dp4a25me authors: Tré‐Hardy, Marie; Wilmet, Alain; Beukinga, Ingrid; Favresse, Julien; Dogné, Jean‐Michel; Douxfils, Jonathan; Blairon, Laurent title: Analytical and clinical validation of an ELISA for specific SARS‐CoV‐2 IgG, IgA, and IgM antibodies date: 2020-07-27 journal: J Med Virol DOI: 10.1002/jmv.26303 sha: c0bac4996407b07bc1c3fd5ba454d75a4145f95e doc_id: 780517 cord_uid: dp4a25me The development of severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) serological tests is massive. The external validation of their performance is needed before use in clinical routine practice. Our study aims at assessing the analytical and clinical performance of two enzyme‐linked immunosorbent assay tests detecting antibodies directed against the virus nucleocapsid protein: The NovaLisa SARS‐CoV‐2 immunoglobulin G (IgG), immunoglobulin A (IgA), and immunoglobulin M (IgM) test (NovaTec) allowing a separate detection of each antibody and the Platelia SARS‐CoV‐2 Total Ab test (Bio‐Rad) detecting total antibodies (IgM, IgA, and IgG). Two‐hundred and eight coronavirus disease 2019 samples from 48 quantitative reverse transcription‐polymerase chain reaction (RT‐qPCR) confirmed patients were used to perform the sensitivity analysis. Non‐SARS‐CoV‐2 sera (n = 79) with a potential cross‐reaction to SARS‐CoV‐2 immunoassays were included in the specificity analysis. In addition, using receiver operator characteristic curves, adapted cut‐off for improvement of the performances were proposed. The kinetics of these antibodies was also assessed over 8 weeks. Two weeks after the RT‐qPCR positive detection, the NovaLisa test shows a sensitivity and specificity of 94.9% (95% confidence interval [CI]: 83.1%‐98.6%) and 96.2% (95% CI: 89.4%‐98.7%) for IgG, of 89.7% (95% CI: 76.4%‐95.9%) and 98.7% (95% CI: 93.2%‐98.8%) for IgA, and of 48.7% (95% CI: 33.9%‐63.8%) and 98.7% (95% CI: 93.2%‐99.8%) for IgM. With the Platelia system, the specificity and sensitivity were 97.4% (95% CI: 92.1%‐99.7%) and 94.9% (95% CI: 87.7%‐98.0%) for total antibodies using the adapted cut‐offs. The NovaLisa and the Platelia tests have satisfactory analytical performances. The clinical performances are excellent for IgG, IgA, and total antibodies especially if the cut‐off is optimized. of 28 April 2020, the region was contributing 63% of the global mortality due to the virus. 3 It is essential for laboratories to independently validate these methods before broad introduction into routine clinical practice. In this context, more and more independent validations of serological tests are published by analyzing the same sample of sera against different techniques but also very often with different antibody targets. [6] [7] [8] [9] [10] [11] [12] The main objective of our study is to assess and compare the analytical and clinical performance of two ELISA tests detecting anti- The secondary objectives are to describe the kinetics of these antibodies over a period of 8 weeks and to clarify the clinical interest of the independent detection of IgG, IgA, and IgM. This retrospective study was conducted from 8 May to 9 June 2020 at the clinical biology laboratory of the Iris Hospitals South (HIS-IZZ, Brussels, Belgium). All the sera (n = 287) originate from blood samples taken during previous clinical requests for diagnostic purposes and were stored in the laboratory serum biobank at −20°C. Among these 287 samples, 79 samples were included in the specificity analysis and were collected before the COVID-19 outbreak. The remaining 208 samples were included in the sensitivity analysis and were collected from patients hospitalized for COVID-19 disease. This study has been approved by the ethical committee of the HIS-IZZ (ethical agreement number: CEHIS/2020-13). Blood samples positive for COVID-19 were collected from symptomatic patients who came to the emergency room. Table 1 reports on the number and characteristics of subjects included in the study for gender, age, extend of disease based on computed tomography scan criteria, length of hospital stay, place of hospitalization and outcome. Patients were considered positive according to the results of the quantitative reverse transcription-polymerase chain reaction (RT-qPCR). The delay between the first onset of symptoms and the RT-qPCR is variable and has been estimated at 4 days (±1 day) in our cohort of 48 patients. Blood samples were collected in serum collection tubes (BD Vacutainer SST II advance, BD, Plymouth, UK) according to procedure previously described. 12 The semi-quantitative analysis of IgG, IgA, and IgM anti-SARS-CoV-2 nucleocapsid antibodies was carried out by the NovaLisa SARS-CoV-2 (COVID-19) IgG, IgA, and IgM test (NovaTec Immundiagnostica GmbH, Dietzenbach, Germany) while the semi-quantitative detection of total anti-SARS-CoV-2 nucleocapsid antibodies (IgM/IgA/IgG) was Seventy-nine samples were tested to assess the cross-reactivity. Seventy-three sera from COVID-19 negative patients but who had other viral, bacterial, parasitic or autoimmune pathologies that could be considered as confounding factors were included in the study. Sera Evaluation of the performance was performed in accordance with the Clinical and Laboratory Standards Institute EP 15-A3 document. 13 The acceptance criteria were defined according to the performance reported by the manufacturer and are summarized in Table 3 . For NovaLisa and Platelia tests, as there were no positive QC with two different levels indicated by the manufacturer, trueness has been estimated by comparing the average value obtained on 20 replicates of two levels of pool patients to target low and high values representative of our patient cohort. Precision has been evaluated by analyzing the repeatability (expressed as intra-run coefficient of variation [CV] ) and the reproducibility (expressed as inter-run CV) of the method. The two levels of pool patients were run in triplicate during 5 consecutive days. The negative control for NovaLisa tests provided by the manufacturer was used as blank sample to determine the limit of blank (LoB) and limit of detection (LoD A sample with a high level of antibodies was run in triplicate (A1, A2, and A3) followed by a negative sample also run in triplicate (B1, B2, and B3). The ratio is calculated using the following equation: (B1 − B3/A3− B3) × 100. Carry-over below 1% is considered satisfactory and is not linked with significant interference. (Table 3) From the results obtained above, interference with certain antibodies or antigens produced following viral, bacterial or parasitic infections or following autoimmune pathologies reveals to be re- IgG tests perform better compared with IgA or IgM ones and show better sensitivity when the samples were taken minimum 2 weeks after the RT-qPCR positive detection. Moreover, a combined IgG/ IgA/IgM test seems to be a better choice in terms of sensitivity than measuring either antibody alone. Insofar as serological tests have no indication in the acute diagnosis of COVID-19, the advantage of detecting each antibody separately seems very limited in clinical practice. At best IgA appears earlier than IgG and are detectable from the 1st week. Regarding the antigenic target, It is essential to compare tests that target the same antibody detection. 15 In this study, we compared for the first time the analytical and clinical performance of two ELISA tests detecting antibodies directed against the nucleocapsid protein. The clinical significance of these differences remains unknown. Do they only witness an infection, or will they witness a protective and lasting immunity over time? However, there is a general consensus that SARS-CoV-2 neutralizing antibody responses are targeting the S protein. 16, 17 Of note, in the longer term, and in the event that a vaccine would become available, measuring antibody responses to the nucleocapsid (N) antigen would be informative because most vaccine candidates are targeting the S protein. 18 Measuring the antibody response may help discriminate between vaccinated (responding to S only) and SARS-CoV-2 exposed individuals (responding to both S and N). To ensure protective and long-lasting immunity, it should be known whether the antibodies are protective and persistent over months. The majority of studies have focused on the clinical performance of serological tests during the first 3 weeks post-symptoms or post-PCR. [19] [20] [21] [22] F I G U R E 3 Comparative ROC curves for IgG, IgA, IgM (NovaTec) and total antibodies (Bio-Rad) n = 287. Ab, antibody; IgA, immunoglobulin A; IgG, immunoglobulin G; IgM, immunoglobulin M; ROC, receiver operator characteristic This study, by assessing the antibody kinetics over a period of 8 weeks provide important data on the persistence of antibodies in infected patients. The delay between the first onset of symptoms and the RT-qPCR is not so variable and has been estimated at 4 days (±1 day) in our cohort of 48 patients. Previous studies have assessed the presence of antibodies in serum collected from 0 up to 49 days post symptoms or post PCR. 23, 24 The kinetics observed in this study is in line with litterature 25 showing a gradual appearance of antibodies between the first and second week post-symptom. A production peak was then observed appearing at the third week followed by a decrease in IgM and IgA from week 4 and 8, respectively ( Figure 2 ). Based on the demographic characteristics of patients included in the study and described in Table 1 , we did not observe any clear association between the IgG, IgM, IgA or total antibodies results and disease severity, although this was already reported in some studies. Finally, the present study has some limitations. First, monitoring of antibody dynamics was extended to a maximum of 56 days post PCR, kinetic analysis over several months will be necessary to confirm the persistence of antibodies. Second, the number of patients included in week 8 is too low to confirm a total disappearance of IgA (n = 2). In addition, the adaptation of the cut-off must consider the population studied. In our study, the cohort studied only focused on symptomatic patients who came to the emergency room. Further investigations are needed to verify whether the appropriate cut-offs are also applicable to pauci-symptomatic and asymptomatic patients. This study is the first to report the external validation of a new NovaLisa SARS-CoV-2 (COVID-19) IgG, IgA, and IgM test (NovaTec) and Platelia SARS-CoV-2 Total Ab method (Bio-Rad) directed against SARS-CoV-2 nucleocapsid. The clinical performances are excellent for IgG, IgA and total antibodies especially if the cut-off is optimized. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-toperson transmission: a study of a family cluster Naming the coronavirus disease (COVID-19) and the virus that causes it; 2020. Technical guidance World Health Organisation. Coronavirus disease (COVID-19) pandemic SARS-CoV-2 diagnostic pipeline. FindDx Towards the next phase: valuation of serological assays for diagnostics and exposure assessment Evaluation of commercial and automated SARS-CoV-2 IgG and IgA ELISAs using coronavirus disease (COVID-19) patient samples Antibody tests in detecting SARS-CoV-2 infection: a meta-analysis Evaluation of two automated and three rapid lateral flow immunoassays for the detection of anti-SARS-CoV-2 antibodies Diagnostic performances and thresholds: the key to harmonization in serological SARS-CoV-2 assays? Performance of SARS-CoV-2 antibody assays in different stages of the infection: comparison of commercial ELISA and rapid tests Validation of a chemiluminescent assay for specific SARS-CoV-2 antibody User Verification of Precision and Estimation of Bias: Approved Guideline. Clinical and Laboratory Standards Institute Guide technique d'Accréditation de vérification (Portée A)/ Validation (Portée B) des méthodes en biologie médicale Brief clinical evaluation of six high-throughput SARS-CoV-2 IgG antibody assays Neutralizing antibodies against SARS-CoV-2 and other human coronaviruses Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study Two linear epitopes on the SARS-CoV-2 spike protein that elicit neutralising antibodies in COVID-19 patients A preliminary study on serological assay for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in 238 admitted hospital patients Antibody responses to SARS-CoV-2 in patients with COVID-19 Serology characteristics of SARS-CoV-2 infection since exposure and post symptom onset Longitudinal monitoring of SARS-CoV-2 IgM and IgG seropositivity to detect COVID-19 Evaluation of the EUROIMMUN Anti-SARS-CoV-2 ELISA assay for detection of IgA and IgG antibodies Clinical performance of the Elecsys electrochemiluminescent immunoassay for the detection of SARS-CoV-2 total antibodies Interpreting diagnostic tests for SARS-CoV-2 Analytical and clinical validation of an ELISA for specific SARS-CoV-2 IgG, IgA and IgM antibodies The authors thank also all the members of the clinical laboratory staff for technical assistance. Among the authors, Jonathan Douxfils is chief executive officer and founder of QUALIblood sa and reports personal fees from Diagnostica Stago, Roche, Roche Diagnostics, Daiichi-Sankyo, and Portola, outside the submitted work. The study was approved by the ethical committee of the Iris Hospitals South.